Refractory msi - H solid tumors prior of PD-(L) 1 therapy

Clinical trials for Refractory msi - H solid tumors prior of PD-(L) 1 therapy explained in plain language.

Never miss a new study

Get alerted when new Refractory msi - H solid tumors prior of PD-(L) 1 therapy trials appear

Sign up with your email to follow new studies for Refractory msi - H solid tumors prior of PD-(L) 1 therapy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug duo takes on Treatment-Resistant cancers

Disease control Ongoing

This phase 2 trial tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink or control advanced solid tumors with a specific genetic feature (MSI-H) that have stopped responding to prior immunotherapy. About 38 adults with these hard-to-treat cancers …

Matched conditions: REFRACTORY MSI - H SOLID TUMORS PRIOR OF PD-(L) 1 THERAPY

Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Jun 27, 2026 11:01 UTC

Refractory msi - H solid tumors prior of PD-(L) 1 therapy

Get alerted when new Refractory msi - H solid tumors prior of PD-(L) 1 therapy trials appear

New drug duo takes on Treatment-Resistant cancers